Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Baxter hemophilia factor VIIa passes Phase III

This article was originally published in Scrip

Executive Summary

Baxter BioScience plans to begin regulatory submissions for the approval of its investigational treatment BAX 817 for hemophiliacs who develop inhibitors, following positive Phase III trial results. The product, a recombinant factor VIIa (rFVIIa) treatment for people with hemophilia A or B, met the primary endpoint of successful resolution of acute bleeding episodes at 12 hours with both on-demand treatment regimens, dosing either 3X90μg/kg or 1X270 μg/kg, with an overall success rate of 92% (98% and 85% in each dosing group, respectively). 89% of patients achieved sustained bleeding control for all acute bleeding episodes 24 hours after infusion. Patients who develop inhibitors to treatments are at increased risk of serious complications from difficult to treat bleeding episodes. No patients developed inhibitors or binding antibodies to BAX817, nor did any discontinue treatment because of an adverse event. The trial was in male patients aged 12-65 covering a six-month period using on-demand therapy. The regulatory submissions will be aligned to ongoing manufacturing expansions.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts